Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049790 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
A Phase 2 study, sponsored by CASI pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00049790: Completed Phase 2 study, sponsored by CASI pharmaceuticals.
NCT00049790 is a Phase 2 study that has completed, run by CASI pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049790, a Phase 2 study, has completed, sponsored by CASI pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG recombinant human Angiostatin protein
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
What the finished NCT00049790 record still lists
NCT00049790 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00049790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00049790 about?
NCT00049790 is a clinical study titled "Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer". The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.
What is the current status of trial NCT00049790?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00049790?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), recombinant human Angiostatin protein (DRUG).
Who is sponsoring clinical trial NCT00049790?
This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.